LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

Ardent Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

December 18, 2024 | Last Trade: US$ 16.61 0.00 0.00

BRENTWOOD, Tenn. / Dec 18, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2025, in San Francisco.

The management team will present at the conference beginning at 2:15 p.m. PT on Tuesday, Jan. 14, 2025. A live audio webcast of the presentation will be available at the investor relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.

In conjunction with the conference, the Ardent management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their J.P. Morgan representative to schedule meetings.

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page